The Journal of Urology
Volume 164, Issue 4 , Pages 1248-1253 , October 2000

INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE

,Accepted 19 May 2000.

REFERENCES 

  1. Rubens RD , Fogelman I . Bone Metastases: Diagnosis and Treatment . London: Springer-Verlag; 1991;
  2. Galasko CSB . The anatomy and pathways of skeletal metastases . In:  Weiss L ,  Gilbert AH editor. Bone Metastasis . Boston: Hall; 1981;p. 49–63 chapt. 4
  3. Dodwell DJ . Malignant bone resorption: cellular and biochemical mechanisms . Ann Oncol . 1992;3:257
  4. Guise TA , Mundy GR . Cancer and bone . Endocr Rev . 1998;19:18
  5. Vinholes J , Coleman R , Eastell R . Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment . Cancer Treat Rev . 1996;22:289
  6. Berruti A , Piovesan A , Torta M , et al.   Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension . Br J Cancer . 1996;73:1581
  7. Urwin GH , Percival RC , Harris S , et al.   Generalised increase in bone resorption in carcinoma of the prostate . Br J Urol . 1985;57:721
  8. Berruti A , Sperone P , Fasolis G , et al.   Pamidronate administration improves the secondary hyperparathyroidism due to “Bone Hunger Syndrome” in a patient with osteoblastic metastases from prostate cancer . Prostate . 1997;33:252
  9. Daniell HW , Dunn SR , Ferguson DW , et al.   Progressive osteoporosis during androgen deprivation therapy for prostate cancer . J Urol . 2000;163:181
  10. Galasko CS . Skeletal metastases . Clin Orthop . 1986;210:18
  11. Coleman RE . Skeletal complications of malignancy . Cancer . 1997;80(suppl.):1588
  12. Robson M , Dawson N . How is androgen-dependent metastatic prostate cancer best treated? . Hematol Oncol Clin North Am . 1996;10:727
  13. Van Hoof VO , Martin M , Blockx P , et al.   Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum . Clin Chem . 1995;41:853
  14. Melkko J , Niemi S , Risteli L , et al.   Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen . Clin Chem . 1990;36:1328
  15. Delmas PD , Demiaux B , Malaval L , et al.   Osteocalcin (or bone gla-protein), a new biological marker for studying bone pathology . Presse Med . 1986;15:643
  16. Risteli J , Elomaa I , Niemi S , et al.   Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation . Clin Chem . 1993;39:635
  17. Kollerup G , Thamsborg G , Bhatia H , et al.   Quantitation of urinary hydroxypyridinium cross-links from collagen by high-performance liquid chromatography . Scand J Clin Lab Invest . 1992;52:657
  18. Paroni R , De Vecchi E , Fermo I , et al.   Total urinary hydroxyproline determined with rapid and simple high-performance liquid chromatography . Clin Chem . 1992;38:407
  19. Hanson DA , Weis MA , Bollen AM , et al.   A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine . J Bone Miner Res . 1992;7:1251
  20. Lipton A , Demers L , Daniloff Y , et al.   Increased urinary excretion of pyridinium cross-links in cancer patients . Clin Chem . 1993;39:614
  21. Bishop MC , Fellows GJ . Urine hydroxyproline excretion—a marker of bone metastases in prostatic carcinoma . Br J Urol . 1977;49:711
  22. Kanis JA , McCloskey EV . Bone turnover and biochemical markers in malignancy . Cancer . 1997;80(suppl.):1538
  23. Oken MM , Czeech RH , Tozmey DC , et al.   Toxicity and response criteria of the Eastern Cooperative Oncology Group . Am J Clin Oncol . 1982;5:649
  24. Coleman RE . Evaluation of bone disease in breast cancer . Breast . 1994;3:73
  25. Siegel S . Nonparametric Statistics for the Behavioral Sciences . New York: McGraw Hill; 1956;
  26. Finn JD . A General Model for Multivariate Analysis . New York: Holt, Rinehart & Winston; 1974;
  27. Lee ET , Desu MM . A computer program for comparing K samples with right-censored data . Comput Programs Biomed . 1972;2:315
  28. deVoogt HJ , Suciu S , Sylvester R , et al.   Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials . J Urol . 1989;141:883
  29. Vassilopoulou-Sellin R , Newman BM , Taylor SH , et al.   Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center . Cancer . 1993;71:1309
  30. Cramer SD , Chen Z , Peehl DM . Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts . J Urol . 1996;156:526
  31. Blumsohn A , Naylor KE , Assiri AM , et al.   Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease . Clin Chem . 1995;41:1592
  32. Body JJ , Bartl R , Burckhardt P , et al.   Current use of bisphosphonates in oncology. International Bone and Cancer Study Group . J Clin Oncol . 1998;16:3890

PII: S0022-5347(05)67149-2

The Journal of Urology
Volume 164, Issue 4 , Pages 1248-1253 , October 2000

Article Tools

* Image Usage & Resolution